Primary lung cancer: Biodistribution and dosimetry of two In-111-labeled monoclonal antibodies

Paul Brown, G. T. Krishnamurthy, F. E. Turner, R. K. Denney, S. A. Gilbert, M. E. Slauson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This study was undertaken to measure the biokinetics and organ dosimetry of indium-111-labeled monoclonal antibodies (MoAbs) with a whole-body gamma camera imaging technique. Twenty patients with primary lung cancer were studied with two different MoAb agents (anti-carcinoembryonic antigen ZCE025 and antiadenocarcinoma LA20207). Imaging was performed at 1, 24, 72, and 144 hours after injection. Scintigraphic wholebody retention was verified by means of comparison with the results from in vitro counting of excreta. Organ retention was verified in an abdominal phantom. The MoAb cleared slowly from the heart and lungs, the brain and spleen showed no clearance, and the liver showed increased activity over the 6-day period. Dosimetry for ZCE025 showed a dose to the liver of 1.3 rad/mCi (0.36 mGy/MBq); heart, 1.5 rad/mCi (0.40 mGy/MBq); spleen, 1.1 rad/mCi (0.29 mGy/MBq); total body, 0.49 rad/mCi (0.13 mGy/MBq); and testes, 0.39 rad/mCi (0.11 mGy/MBq). The dosimetry for LA20207 was similar.

Original languageEnglish (US)
Pages (from-to)701-705
Number of pages5
JournalRadiology
Volume173
Issue number3
StatePublished - 1989

Fingerprint

Lung Neoplasms
Spleen
Monoclonal Antibodies
Indium
Liver
Carcinoembryonic Antigen
Radionuclide Imaging
Testis
Lung
Injections
Brain
In Vitro Techniques

Keywords

  • Lung neoplasms, radionuclide studies
  • Monoclonal antibodies
  • Radionuclide imaging, computer assisted
  • Radionuclide imaging, dosimetry
  • Radionuclide imaging, radiation dose

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Brown, P., Krishnamurthy, G. T., Turner, F. E., Denney, R. K., Gilbert, S. A., & Slauson, M. E. (1989). Primary lung cancer: Biodistribution and dosimetry of two In-111-labeled monoclonal antibodies. Radiology, 173(3), 701-705.

Primary lung cancer : Biodistribution and dosimetry of two In-111-labeled monoclonal antibodies. / Brown, Paul; Krishnamurthy, G. T.; Turner, F. E.; Denney, R. K.; Gilbert, S. A.; Slauson, M. E.

In: Radiology, Vol. 173, No. 3, 1989, p. 701-705.

Research output: Contribution to journalArticle

Brown, P, Krishnamurthy, GT, Turner, FE, Denney, RK, Gilbert, SA & Slauson, ME 1989, 'Primary lung cancer: Biodistribution and dosimetry of two In-111-labeled monoclonal antibodies', Radiology, vol. 173, no. 3, pp. 701-705.
Brown P, Krishnamurthy GT, Turner FE, Denney RK, Gilbert SA, Slauson ME. Primary lung cancer: Biodistribution and dosimetry of two In-111-labeled monoclonal antibodies. Radiology. 1989;173(3):701-705.
Brown, Paul ; Krishnamurthy, G. T. ; Turner, F. E. ; Denney, R. K. ; Gilbert, S. A. ; Slauson, M. E. / Primary lung cancer : Biodistribution and dosimetry of two In-111-labeled monoclonal antibodies. In: Radiology. 1989 ; Vol. 173, No. 3. pp. 701-705.
@article{cc056278406b471fbd8728e8f94391cb,
title = "Primary lung cancer: Biodistribution and dosimetry of two In-111-labeled monoclonal antibodies",
abstract = "This study was undertaken to measure the biokinetics and organ dosimetry of indium-111-labeled monoclonal antibodies (MoAbs) with a whole-body gamma camera imaging technique. Twenty patients with primary lung cancer were studied with two different MoAb agents (anti-carcinoembryonic antigen ZCE025 and antiadenocarcinoma LA20207). Imaging was performed at 1, 24, 72, and 144 hours after injection. Scintigraphic wholebody retention was verified by means of comparison with the results from in vitro counting of excreta. Organ retention was verified in an abdominal phantom. The MoAb cleared slowly from the heart and lungs, the brain and spleen showed no clearance, and the liver showed increased activity over the 6-day period. Dosimetry for ZCE025 showed a dose to the liver of 1.3 rad/mCi (0.36 mGy/MBq); heart, 1.5 rad/mCi (0.40 mGy/MBq); spleen, 1.1 rad/mCi (0.29 mGy/MBq); total body, 0.49 rad/mCi (0.13 mGy/MBq); and testes, 0.39 rad/mCi (0.11 mGy/MBq). The dosimetry for LA20207 was similar.",
keywords = "Lung neoplasms, radionuclide studies, Monoclonal antibodies, Radionuclide imaging, computer assisted, Radionuclide imaging, dosimetry, Radionuclide imaging, radiation dose",
author = "Paul Brown and Krishnamurthy, {G. T.} and Turner, {F. E.} and Denney, {R. K.} and Gilbert, {S. A.} and Slauson, {M. E.}",
year = "1989",
language = "English (US)",
volume = "173",
pages = "701--705",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "3",

}

TY - JOUR

T1 - Primary lung cancer

T2 - Biodistribution and dosimetry of two In-111-labeled monoclonal antibodies

AU - Brown, Paul

AU - Krishnamurthy, G. T.

AU - Turner, F. E.

AU - Denney, R. K.

AU - Gilbert, S. A.

AU - Slauson, M. E.

PY - 1989

Y1 - 1989

N2 - This study was undertaken to measure the biokinetics and organ dosimetry of indium-111-labeled monoclonal antibodies (MoAbs) with a whole-body gamma camera imaging technique. Twenty patients with primary lung cancer were studied with two different MoAb agents (anti-carcinoembryonic antigen ZCE025 and antiadenocarcinoma LA20207). Imaging was performed at 1, 24, 72, and 144 hours after injection. Scintigraphic wholebody retention was verified by means of comparison with the results from in vitro counting of excreta. Organ retention was verified in an abdominal phantom. The MoAb cleared slowly from the heart and lungs, the brain and spleen showed no clearance, and the liver showed increased activity over the 6-day period. Dosimetry for ZCE025 showed a dose to the liver of 1.3 rad/mCi (0.36 mGy/MBq); heart, 1.5 rad/mCi (0.40 mGy/MBq); spleen, 1.1 rad/mCi (0.29 mGy/MBq); total body, 0.49 rad/mCi (0.13 mGy/MBq); and testes, 0.39 rad/mCi (0.11 mGy/MBq). The dosimetry for LA20207 was similar.

AB - This study was undertaken to measure the biokinetics and organ dosimetry of indium-111-labeled monoclonal antibodies (MoAbs) with a whole-body gamma camera imaging technique. Twenty patients with primary lung cancer were studied with two different MoAb agents (anti-carcinoembryonic antigen ZCE025 and antiadenocarcinoma LA20207). Imaging was performed at 1, 24, 72, and 144 hours after injection. Scintigraphic wholebody retention was verified by means of comparison with the results from in vitro counting of excreta. Organ retention was verified in an abdominal phantom. The MoAb cleared slowly from the heart and lungs, the brain and spleen showed no clearance, and the liver showed increased activity over the 6-day period. Dosimetry for ZCE025 showed a dose to the liver of 1.3 rad/mCi (0.36 mGy/MBq); heart, 1.5 rad/mCi (0.40 mGy/MBq); spleen, 1.1 rad/mCi (0.29 mGy/MBq); total body, 0.49 rad/mCi (0.13 mGy/MBq); and testes, 0.39 rad/mCi (0.11 mGy/MBq). The dosimetry for LA20207 was similar.

KW - Lung neoplasms, radionuclide studies

KW - Monoclonal antibodies

KW - Radionuclide imaging, computer assisted

KW - Radionuclide imaging, dosimetry

KW - Radionuclide imaging, radiation dose

UR - http://www.scopus.com/inward/record.url?scp=0024408602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024408602&partnerID=8YFLogxK

M3 - Article

C2 - 2510212

AN - SCOPUS:0024408602

VL - 173

SP - 701

EP - 705

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 3

ER -